Long-term safety assessment of niraparib in patients with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial

Mirza,; Dørum, Anne; Benigno, Benedict B.; Mahner, Sven; Bessette, Paul; Barcelo, IM Bover; Berton, Dominique; Ledermann, Jonathan A.; Rimel, B.J.; Herrstedt, Jørn; Canzler, Ulrich; Vázquez, Isabel; Kalbacher, Elsa; Buscema, Joseph; Lorusso, D.; Debruyne, Philip R.; Bruchim, Ilan; Guo, Wei; Gupta, Dhiraj; Jong, Fa de; Matulonis, U.

doi:10.1136/ijgc-2019-esgo.18

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The AE profiles of PARP inhibitors as maintenance treatment in the recurrent setting are similar to each other, with most AEs being low grade (grade 1 or 2) and manageable with supportive care and/or dose modification [18][19][20][21]35,38,44,45]. The non-hematologic AEs most frequently associated with PARP inhibitors are gastrointestinal sideeffects, including nausea (any grade: 71-76%; grade ≥3: 2-4%), vomiting (any grade: 34-37%; grade ≥3: 2-4%), constipation (any grade: 21-40%; grade ≥3: 0-2%), and diarrhea (any grade: 19-33%; grade ≥3: < 1-2%) ( Fig.…”

Section: Safety Of Maintenance Therapy For Recurrent Ovarian Cancermentioning

confidence: 85%

Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatment

Mirza

Pignata

Walther

et al. 2020

Cancer Treatment Reviews

View full text Add to dashboard Cite

Most women with advanced ovarian cancer respond to initial treatment, consisting of surgical resection and ≈6 cycles of platinum-based chemotherapy. However, disease recurrence occurs in most patients, and subsequent therapies become necessary. Historically, close monitoring following treatment (active surveillance) was the only available option, as continued maintenance chemotherapy treatment led to increased toxicity without providing any meaningful clinical benefit. Recently, targeted therapy with the angiogenesis inhibitor bevacizumab and the poly(ADP-ribose) polymerase (PARP) inhibitors olaparib, niraparib, and rucaparib have demonstrated significant clinical benefits as maintenance treatment for recurrent disease. Despite consensus guidelines recommending their use, maintenance treatments are currently underutilized. Here, we review evidence from pivotal clinical trials of approved second-line maintenance treatments demonstrating efficacy in terms of progression-free survival and postprogression efficacy outcomes for patients with recurrent ovarian cancer. Adverse events frequently associated with bevacizumab include hypertension, proteinuria, and noncentral nervous system bleeding, whereas PARP inhibitors are associated with nausea, vomiting, fatigue, and anemia. Patient-centered outcomes analyses show that PARP inhibitors provide significant benefits to patient health status, even when accounting for the toxicities associated with treatment. Many factors influence the selection of second-line maintenance treatment for patients with recurrent ovarian cancer, including the maintenance treatment received in the first-line setting. Overall, targeted maintenance treatment represents a new standard of care for patients with ovarian cancer, and we recommend that maintenance treatment should be offered to all eligible patients with recurrent ovarian cancer.

show abstract

Section: Safety Of Maintenance Therapy For Recurrent Ovarian Cancermentioning

confidence: 85%

Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatment

Mirza

Pignata

Walther

et al. 2020

Cancer Treatment Reviews

View full text Add to dashboard Cite

show abstract

Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer

Tattersall

Ryan

Wiggans

et al. 2022

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

Long-term safety assessment of niraparib in patients with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial

Cited by 2 publications

References 0 publications

Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatment

Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatment

Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer

Contact Info

Product

Resources

About